Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Inotuzumab B1931036 (ALL)

Clinical study of inotuzumab ozogamicin in children with a diagnosis of first relapse high-risk acute lymphoblastic leukemia.
Who can enter
  • Children with confirmed diagnosis of high-risk first relapse of acute lymphoblastic leukemia (ALL)
  • Age: 1 to <18 years


There is an urgent need to improve the efficacy (removal of cancer cells) of reinduction therapy and reduce treatment side effects. Therefore, the purpose of this study is to evaluate whether inotuzumab ozogamicin is more effective in removing cancer cells after one treatment cycle than ALLR3, the standard multi-agent chemotherapy regimen.


Children with ALL are currently treated with different treatment protocols. All children start with what is known as induction treatment. Treatment with ALLR3 chemotherapy is considered the standard first-line treatment for ALL by many physicians and study groups.

However, in high-risk patients ALLR3 has not been as effective in removing cancer cells with fewer side effects as it has been in other risk groups. Modern treatment approaches for ALL focus on pre-transplant removal of cancer cells, especially for patients with high-risk disease characteristics. Inotuzumab ozogamicin is expected to improve response to treatment, with fewer side effects after one treatment cycle.

Bone marrow, blood and cerebrospinal fluid samples will be collected several times during treatment to determine response rates.

The study is being conducted in 60 or more research sites in about 19 countries, mainly in Europe. In the Netherlands, the study is conducted at the Prinses Máxima Center.

In order to participate in a study please refer to your/your child’s doctor.
For international patients: please feel welcome to contact our International Office.

Last reviewed
September 5, 2023